Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Fish and Richardson
Colorcon
Citi
Dow
Accenture
Cerilliant
Chinese Patent Office
Fuji
Johnson and Johnson
Federal Trade Commission

Generated: October 18, 2017

DrugPatentWatch Database Preview

Biocryst Company Profile

« Back to Dashboard

What is the competitive landscape for BIOCRYST, and when can generic versions of BIOCRYST drugs launch?

BIOCRYST has one approved drug.

There are three US patents protecting BIOCRYST drugs.

There are fifty-four patent family members on BIOCRYST drugs in twenty-seven countries.

Summary for Applicant: Biocryst

International Patents:54
US Patents:3
Tradenames:1
Ingredients:1
NDAs:1
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Biocryst
RAPIVAB
peramivir
SOLUTION;IV (INFUSION)206426-001Dec 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Biocryst Drugs

Country Document Number Estimated Expiration
South Korea20140132778► Subscribe
Australia2007215156► Subscribe
Mexico2008010394► Subscribe
Cyprus1109153► Subscribe
Hong Kong1212250► Subscribe
Romania121815► Subscribe
South Africa200809012► Subscribe
Australia2006341592► Subscribe
South Korea20160129105► Subscribe
Spain2324746► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Fish and Richardson
Moodys
US Army
Merck
Julphar
Medtronic
Federal Trade Commission
Queensland Health
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot